Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement with Amgen to Evaluate Zocilurtatug Pelitecan in Combination with Imdelltra April 7, 2026
First Patient Dosed in Ph 3 RASolute 303 Trial of Daraxonrasib in 1L Metastatic Pancreatic Cancer April 7, 2026
Neoadjuvant Anbenitamab Meets Primary Endpoint in Ph 3 HER2-Positive Breast Cancer Trial April 7, 2026
Rinzimetostat RP3D in Combination with Darolutamide selected for Himalayas-1 Ph 3 Global Study with Dose Optimization Data April 7, 2026
Imfinzi + Imjudo combined with lenvatinib and TACE demonstrated a statistically significant PFS improvement in embolisation-eligible unresectable liver cancer in EMERALD-3 Ph 3 trial April 7, 2026
CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer April 7, 2026
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Novel ADC Payload Targeting RNA Splicing April 7, 2026
Stipple Bio Launches with $100M Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline April 7, 2026
OnKure Therapeutics Announces Oversubscribed $150M Private Placement to Advance Two PI3Kα Pan-Mutant Selective Inhibitors in Breast Cancer and Vascular Anomalies April 7, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer April 7, 2026
First-Patient-In for Ph 1 Trial of IDE574 in Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer April 7, 2026
First-Patient-In for Ph 1 Combination Study of IDE849 and IDE161 in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma April 7, 2026
OS beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of Ph 2 THIO-101 trial in NSCLC reported April 7, 2026
Type C FDA Meeting Announced to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer April 7, 2026
FDA Accepts Priority Review of NDA for Lirafugratinib as 2L Cholangiocarcinoma Treatment April 7, 2026
FDA granted Breakthrough Therapy Designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG) April 7, 2026
